Spruce Biosciences, Inc.
corporate_fare Company Profile
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for SPRB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for SPRB spans 10-Q, 8-K, 424B5, DEF 14A.
Recent high-impact activity:
- Spruce 10-Q: $24M Q3 Loss, $87.7M Cash, Going-Concern Warning Ahead of December BLA
- Spruce Q3 Loss Widens to $24M; Avenue Loan Amended, Adrenyx Spin Terms Set
- Spruce Biosciences Posts $24M Q3 Loss, Cash of $87.7M Ahead of December BLA Filing
- Spruce Spins Out CRHX-101 Into Adrenyx, Targets Two Public Companies by H1 2027
- FDA Endorses Spruce's BLA Plan for TA-ERT; Submission on Track for Q4
Financial Snapshot
Short Interest & Short Volume
6.95 days to coverFINRA reported short interest of 531,380 shares in SPRB as of the October 30, 2026 settlement, a 1.8% increase from the prior period — about 7.0 days to cover at its recent average daily volume. On November 20, 2026, 56.9% of SPRB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.